

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

UPDATE ON THE FORMATION OF FUND

Reference is made to the announcement of China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 30 October 2025 (the “**Announcement**”). Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the Company has been notified that the relevant industry and commerce administration registration for the Fund and the Fund’s filing with the Asset Management Association of China (中國證券投資基金業協會) (the “**AMAC**”) pursuant to the applicable PRC laws and regulations have been completed, and the Fund has obtained the Private Investment Fund Filing Record (SBML96) issued by the AMAC.

As disclosed in the Announcement, Shenzhen CR Capital will be entrusted as the fund manager of the Fund. Shenzhen CR Capital is a company established in the PRC and is a fund manager licensed with the AMAC. Shenzhen CR Capital has over 10 years of experience in managing private funds, cumulatively investing in over 100 projects, covering industries such as pharmaceuticals and healthcare, semiconductors, new materials, new energy and digital technology. As of 30 September 2025, Shenzhen CR Capital cumulatively managed 17 domestic funds, and the cumulative subscription

amount of such funds exceeded RMB20 billion. In entrusting the fund manager of the Fund, factors taken into consideration included Shenzhen CR Capital's background, qualification, past performance and experience, including among others (i) the years of experience and reputation it has in managing funds in the PRC, as well as the number of funds it has managed and number of projects it has invested in; (ii) its expertise in managing investments in pharmaceuticals and healthcare industries, considering that it has managed dedicated funds investing in such fields; (iii) the amount and scale of investments managed by Shenzhen CR Capital, such as the subscription amount of funds it has managed; and (iv) Shenzhen CR Capital being also the fund manager of China Re-sources Pharmaceutical (Shantou) Industrial Investment Fund LLP ("**CR Pharmaceutical Industrial Fund**"), a fund that the Group has invested in. CR Pharmaceutical Industrial Fund has achieved good investment returns for the Group, and through such fund the Group has established a positive cooperative relationship with Shenzhen CR Capital. Having considered such factors, Shenzhen CR Capital will be entrusted as the fund manager of the Fund.

In addition, as disclosed in the Announcement, CR Pharm (Shantou), a wholly-owned subsidiary of the Company, will act as one of the general partners and executive partners of the Fund. As a general partner and executive partner, CR Pharm (Shantou) will be responsible for and actively participate in, among others, advising and consulting on the daily management of the Fund, as well as sourcing projects for the Fund and coordinating on post-investment cooperation. The Fund is expected to invest in the fields of synthetic biology, innovative drugs and biotechnology. Given such roles and participation of the Group in the Fund, despite the fact that the Fund will be accounted as an equity investment of the Company, through the participation of CR Pharm (Shantou) in the Fund, it is expected that the Fund will connect the Group with companies, products and opportunities relevant to the synthetic biology industry, as well as access to the resources and policy support for Hohhot's synthetic biology industry development, thereby achieving the Group's objectives of forming a synthetic biology industrialization platform in Hohhot, among others.

Among the parties to the Limited Partnership Agreement, the SLP is an employee co-investment platform established and managed by employees of Shenzhen CR Capital, which is the fund manager of the Fund. The primary purpose of establishing the SLP and its capital contribution to the Fund as a limited partner is to incentivise and align the interests of employees involved in management of the Fund and the interests of the Fund. Pursuant to the limited partnership agreement of the SLP, (i) the general partner of the SLP is Mr. Sun Meng (孫萌), an employee of Shenzhen CR Capital, holding 70% of the interests in the SLP; and (ii) the limited partner of the SLP is Mr. Wang Hao (王昊), an employee of Shenzhen CR Capital, holding 30% of the interest in the SLP. Such investments in the SLP are funded by the employees' own resources, and the SLP is not owned or controlled by Shenzhen CR Capital.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 30 December 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Cheng Jie and Mr. Liu Changan as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.